Squarepoint Ops LLC Sells 64,458 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Squarepoint Ops LLC lowered its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 71.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 25,285 shares of the life sciences company's stock after selling 64,458 shares during the quarter. Squarepoint Ops LLC's holdings in Integra LifeSciences were worth $573,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of IART. Quadrant Capital Group LLC lifted its stake in Integra LifeSciences by 5,960.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after buying an additional 1,371 shares in the last quarter. Sterling Capital Management LLC lifted its stake in Integra LifeSciences by 821.7% in the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after buying an additional 1,931 shares in the last quarter. Covestor Ltd lifted its stake in Integra LifeSciences by 61.8% in the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after buying an additional 2,071 shares in the last quarter. Empowered Funds LLC bought a new position in Integra LifeSciences in the fourth quarter valued at approximately $180,000. Finally, NorthRock Partners LLC bought a new position in Integra LifeSciences in the fourth quarter valued at approximately $251,000. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences Stock Up 1.5%

Shares of IART stock traded up $0.19 during trading on Thursday, reaching $13.29. The company's stock had a trading volume of 901,576 shares, compared to its average volume of 1,034,752. The business has a fifty day moving average price of $15.50 and a 200-day moving average price of $20.72. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -147.65, a price-to-earnings-growth ratio of 0.73 and a beta of 1.16. Integra LifeSciences Holdings Co. has a one year low of $11.60 and a one year high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm had revenue of $382.65 million for the quarter, compared to the consensus estimate of $381.17 million. During the same period last year, the company posted $0.55 earnings per share. The business's revenue was up 3.7% compared to the same quarter last year. Analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

IART has been the topic of a number of research reports. Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. JMP Securities cut their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. Wells Fargo & Company cut their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Truist Financial cut their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. Four equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $18.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.